Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) have been given an average rating of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company.

Several brokerages have recently commented on BIOVF. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. HC Wainwright began coverage on Swedish Orphan Biovitrum in a research note on Wednesday, May 6th. They set a “buy” rating for the company.

Swedish Orphan Biovitrum Price Performance

OTCMKTS:BIOVF opened at $48.00 on Friday. The firm has a market capitalization of $17.09 billion, a price-to-earnings ratio of 160.00 and a beta of 0.36. Swedish Orphan Biovitrum has a twelve month low of $27.06 and a twelve month high of $48.00. The stock’s 50 day moving average price is $46.24 and its two-hundred day moving average price is $40.76. The company has a quick ratio of 0.47, a current ratio of 0.70 and a debt-to-equity ratio of 0.19.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.07. The firm had revenue of $755.76 million for the quarter, compared to analyst estimates of $749.76 million. Swedish Orphan Biovitrum had a return on equity of 16.66% and a net margin of 3.37%. Equities research analysts expect that Swedish Orphan Biovitrum will post 2.22 earnings per share for the current fiscal year.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm?based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high?value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in?licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto?inflammatory conditions.